Australia markets closed
  • ALL ORDS

    7,270.00
    +3.40 (+0.05%)
     
  • ASX 200

    7,068.80
    +3.60 (+0.05%)
     
  • AUD/USD

    0.6443
    +0.0026 (+0.40%)
     
  • OIL

    90.33
    +0.70 (+0.78%)
     
  • GOLD

    1,944.90
    +5.30 (+0.27%)
     
  • Bitcoin AUD

    41,296.43
    +37.44 (+0.09%)
     
  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     
  • AUD/EUR

    0.6049
    +0.0036 (+0.60%)
     
  • AUD/NZD

    1.0810
    -0.0001 (-0.01%)
     
  • NZX 50

    11,372.62
    +53.88 (+0.48%)
     
  • NASDAQ

    14,701.10
    +6.85 (+0.05%)
     
  • FTSE

    7,683.91
    +5.29 (+0.07%)
     
  • Dow Jones

    33,963.84
    -106.58 (-0.31%)
     
  • DAX

    15,557.29
    -14.57 (-0.09%)
     
  • Hang Seng

    18,057.45
    +402.04 (+2.28%)
     
  • NIKKEI 225

    32,402.41
    -168.62 (-0.52%)
     

Shareholders in Twist Bioscience (NASDAQ:TWST) are in the red if they invested a year ago

Investing in stocks comes with the risk that the share price will fall. And unfortunately for Twist Bioscience Corporation (NASDAQ:TWST) shareholders, the stock is a lot lower today than it was a year ago. The share price is down a hefty 65% in that time. We note that it has not been easy for shareholders over three years, either; the share price is down 49% in that time. Furthermore, it's down 26% in about a quarter. That's not much fun for holders.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

View our latest analysis for Twist Bioscience

Twist Bioscience wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last twelve months, Twist Bioscience increased its revenue by 48%. That's a strong result which is better than most other loss making companies. Meanwhile, the share price slid 65%. This could mean hype has come out of the stock because the bottom line is concerning investors. We'd definitely consider it a positive if the company is trending towards profitability. If you can see that happening, then perhaps consider adding this stock to your watchlist.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free report showing analyst forecasts should help you form a view on Twist Bioscience

A Different Perspective

The last twelve months weren't great for Twist Bioscience shares, which performed worse than the market, costing holders 65%. The market shed around 14%, no doubt weighing on the stock price. Shareholders have lost 14% per year over the last three years, so the share price drop has become steeper, over the last year; a potential symptom of as yet unsolved challenges. Although Baron Rothschild famously said to "buy when there's blood in the streets, even if the blood is your own", he also focusses on high quality stocks with solid prospects. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should be aware of the 2 warning signs we've spotted with Twist Bioscience .

Twist Bioscience is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here